Quadrant stock closed at Rs 319.50 in the previous session. Market cap of the firm stood at Rs 1278 crore.

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

BioMarin Pharmaceutical's (BMRN) shares fell on Monday after the company said it would discontinue dosing and enrollment in ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—currently approved in achondroplasia, a ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Q4 2025 earnings call recap: pemvidutide Phase III MASH plans, Phase II data, FDA status, cash runway to 2028—read now.

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

DYNAMIKA™ delivers SOC 2 Type II–certified, AI‑driven imaging workflows, giving pharma and biotech secure, compliant ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.